

IMMUNOLOGIC

→ **Antiviral prophylactic** therapy is recommended for patients who are seropositive for cytomegalovirus (CMV) at the time of transplant and for CMV-seronegative patients scheduled to receive a kidney from a CMV-seropositive donor

Drug	Dose (normal creatinine clearance)	>60 mL/min	40–60 mL/min	25–40 mL/min	<10 mL/min dialysis
intravenous ganciclovir	5 mg/kg twice per day	2.5 mg/kg twice per day	2.5 mg/kg/day	1.25 mg/kg/day	1.25 mg/kg after dialysis

→ Administration of prophylactic antifungal and antibiotic therapy if indicated

-Cber, & Fda. (n.d.). *Package Insert - Immunosuppression Thymoglobulin*.
www.fda.gov/medwatch. (<https://www.fda.gov/media/74641/download>)

Azevedo, L. S., Pierrotti, L. C., Abdala, E., Costa, S. F., Strabelli, T. M., Campos, S. V., Ramos, J. F., Latif, A. Z., Litvinov, N., Maluf, N. Z., Caiaffa Filho, H. H., Pannuti, C. S., Lopes, M. H., Santos, V. A., Linardi, C., Yasuda, M. A., & Marques, H. H. (2015). Cytomegalovirus infection in transplant recipients. *Clinics (Sao Paulo, Brazil)*, 70(7), 515–523.
[https://doi.org/10.6061/clinics/2015\(07\)09](https://doi.org/10.6061/clinics/2015(07)09)

